IL258224B - Compounds for detecting and treating growth hormone deficiency - Google Patents

Compounds for detecting and treating growth hormone deficiency

Info

Publication number
IL258224B
IL258224B IL258224A IL25822418A IL258224B IL 258224 B IL258224 B IL 258224B IL 258224 A IL258224 A IL 258224A IL 25822418 A IL25822418 A IL 25822418A IL 258224 B IL258224 B IL 258224B
Authority
IL
Israel
Prior art keywords
identifying
compounds
growth hormone
hormone deficiency
treating growth
Prior art date
Application number
IL258224A
Other languages
English (en)
Hebrew (he)
Other versions
IL258224A (en
Original Assignee
Ammonett Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ammonett Pharm Llc filed Critical Ammonett Pharm Llc
Publication of IL258224A publication Critical patent/IL258224A/en
Publication of IL258224B publication Critical patent/IL258224B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/61—Growth hormones [GH] (Somatotropin)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IL258224A 2015-09-21 2018-03-19 Compounds for detecting and treating growth hormone deficiency IL258224B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562221191P 2015-09-21 2015-09-21
US201662289221P 2016-01-30 2016-01-30
PCT/US2016/052800 WO2017053373A1 (en) 2015-09-21 2016-09-21 Detecting and treating growth hormone deficiency

Publications (2)

Publication Number Publication Date
IL258224A IL258224A (en) 2018-05-31
IL258224B true IL258224B (en) 2021-10-31

Family

ID=58276481

Family Applications (1)

Application Number Title Priority Date Filing Date
IL258224A IL258224B (en) 2015-09-21 2018-03-19 Compounds for detecting and treating growth hormone deficiency

Country Status (23)

Country Link
US (5) US9763919B2 (enExample)
EP (3) EP3352752B1 (enExample)
JP (5) JP6816149B2 (enExample)
KR (4) KR20230116961A (enExample)
CN (2) CN108348501A (enExample)
AU (5) AU2016328969B2 (enExample)
CA (1) CA2998523C (enExample)
CY (1) CY1125183T1 (enExample)
DK (2) DK3939590T3 (enExample)
ES (2) ES2967259T3 (enExample)
FI (1) FI3939590T3 (enExample)
HR (1) HRP20220317T1 (enExample)
HU (2) HUE065224T2 (enExample)
IL (1) IL258224B (enExample)
LT (1) LT3352752T (enExample)
PL (2) PL3939590T3 (enExample)
PT (2) PT3939590T (enExample)
RS (1) RS62988B1 (enExample)
SG (2) SG10202010598SA (enExample)
SI (1) SI3352752T1 (enExample)
SM (1) SMT202200167T1 (enExample)
UA (1) UA123865C2 (enExample)
WO (1) WO2017053373A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11234969B2 (en) * 2016-01-30 2022-02-01 Lumos Pharma, Inc. Detecting and treating growth hormone deficiency
CN108348501A (zh) * 2015-09-21 2018-07-31 埃莫奈特药业有限责任公司 检测和治疗生长激素缺乏症
US10288629B1 (en) * 2017-12-19 2019-05-14 Aeterna Zentaris, Inc. Method of assessing growth hormone deficiency in humans by a macimorelin containing composition
EP3840854A4 (en) 2018-08-20 2022-06-29 Bessor Pharma, LLC Novel cannabinoids and cannabinoid acids and their derivatives
US11644474B2 (en) * 2020-07-22 2023-05-09 Æterna Zentaris Gmbh Use of macimorelin in assessing growth hormone deficiency in children
GEAP202516774A (en) 2022-11-03 2025-06-25 Lumos Pharma Inc Compactable oral formulations of ibutamoren

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225096A1 (en) * 2000-05-31 2003-12-04 John Hakkinen Compositions and methods for stimulating gastrointestinal motility
US20070037861A1 (en) * 2003-09-19 2007-02-15 Pfizer Health Ab Enhanced method of treatment of growth disorders
US20150119327A1 (en) * 2012-04-25 2015-04-30 The Regents Of The University Of California Drug screening platform for rett syndrome

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0650597A4 (en) * 1992-06-29 1996-12-18 Univ South Florida DIAGNOSTIC METHOD FOR EVALUATING THE AETIOLOGY OF MINOR GROWTH.
US5756507A (en) 1995-12-14 1998-05-26 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
AU758160B2 (en) * 1997-08-22 2003-03-20 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives
ATE302181T1 (de) * 2000-06-13 2005-09-15 Zentaris Gmbh Verbindungen zur stimulation der sekretion von wachstumshormonen
AU2004288831B2 (en) * 2003-11-12 2010-08-26 Phenomix Corporation Heterocyclic boronic acid compounds
GB0603295D0 (en) 2006-02-18 2006-03-29 Ardana Bioscience Ltd Methods and kits
US11234969B2 (en) * 2016-01-30 2022-02-01 Lumos Pharma, Inc. Detecting and treating growth hormone deficiency
CN108348501A (zh) * 2015-09-21 2018-07-31 埃莫奈特药业有限责任公司 检测和治疗生长激素缺乏症

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225096A1 (en) * 2000-05-31 2003-12-04 John Hakkinen Compositions and methods for stimulating gastrointestinal motility
US20070037861A1 (en) * 2003-09-19 2007-02-15 Pfizer Health Ab Enhanced method of treatment of growth disorders
US20150119327A1 (en) * 2012-04-25 2015-04-30 The Regents Of The University Of California Drug screening platform for rett syndrome

Also Published As

Publication number Publication date
PT3352752T (pt) 2022-03-09
UA123865C2 (uk) 2021-06-16
US20170079961A1 (en) 2017-03-23
SG10202010598SA (en) 2020-11-27
AU2016328969B2 (en) 2020-10-08
ES2967259T3 (es) 2024-04-29
US12539293B2 (en) 2026-02-03
CN108348501A (zh) 2018-07-31
JP2024026112A (ja) 2024-02-28
PL3939590T3 (pl) 2024-03-25
EP3939590B1 (en) 2023-11-29
ES2908423T3 (es) 2022-04-29
PL3352752T3 (pl) 2022-04-19
HUE057831T2 (hu) 2022-06-28
HRP20220317T1 (hr) 2022-05-13
FI3939590T3 (fi) 2023-12-14
KR20250102122A (ko) 2025-07-04
AU2020233715B2 (en) 2021-09-30
CY1125183T1 (el) 2023-06-09
SG10201902424TA (en) 2019-04-29
JP7104768B2 (ja) 2022-07-21
HK1263178A1 (zh) 2020-01-31
AU2024201658C1 (en) 2026-02-12
AU2025237934A1 (en) 2025-10-16
AU2024201658A1 (en) 2024-04-04
JP7389862B2 (ja) 2023-11-30
US20220142989A1 (en) 2022-05-12
US10105352B2 (en) 2018-10-23
US10898472B2 (en) 2021-01-26
DK3939590T3 (da) 2023-12-18
AU2016328969A1 (en) 2018-04-26
KR20180082428A (ko) 2018-07-18
EP3352752A1 (en) 2018-08-01
IL258224A (en) 2018-05-31
JP2018529766A (ja) 2018-10-11
SMT202200167T1 (it) 2022-05-12
KR102385669B1 (ko) 2022-04-13
CA2998523C (en) 2023-08-01
NZ741142A (en) 2025-05-02
HUE065224T2 (hu) 2024-05-28
RS62988B1 (sr) 2022-03-31
JP2021063096A (ja) 2021-04-22
EP4296679A2 (en) 2023-12-27
US20190015394A1 (en) 2019-01-17
US20180071266A1 (en) 2018-03-15
CA2998523A1 (en) 2017-03-30
JP7724831B2 (ja) 2025-08-18
KR20220047407A (ko) 2022-04-15
AU2020233715A1 (en) 2020-10-22
AU2021254600A1 (en) 2021-11-18
US9763919B2 (en) 2017-09-19
KR20230116961A (ko) 2023-08-04
LT3352752T (lt) 2022-04-11
WO2017053373A1 (en) 2017-03-30
CN116459250A (zh) 2023-07-21
EP3939590A1 (en) 2022-01-19
AU2024201658B2 (en) 2025-10-30
JP2022163012A (ja) 2022-10-25
EP3352752B1 (en) 2021-12-22
AU2021254600B2 (en) 2024-02-15
KR102560838B1 (ko) 2023-07-27
SI3352752T1 (sl) 2022-05-31
JP2025170274A (ja) 2025-11-18
PT3939590T (pt) 2024-01-23
JP6816149B2 (ja) 2021-01-20
EP3352752A4 (en) 2019-06-12
US20250213536A1 (en) 2025-07-03
DK3352752T3 (da) 2022-02-28
EP4296679A3 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
EP3703607C0 (en) AUTOMATIC TREATMENT PLANNING
IL262225A (en) Methods for monitoring and treating cancer
EP3541587C0 (en) EQUIPMENT FOR PROCESSING OBJECTS
EP3742855C0 (en) UPLINK TRANSMISSION MANAGEMENT TECHNIQUES
EP3223712C0 (en) THERAPEUTIC HEAT TREATMENT DEVICES
PL3301990T3 (pl) Sposób i przyrząd do ustanawiania powiązania
IL251215B (en) Cannabinoid composition and method for treating pain
SG11201707421WA (en) Method and facility for breeding insects
BR112015002968A2 (pt) dispositivo para vestir e método para fabricar o mesmo
IL278247B (en) mct4 inhibitors to treat the disease
IL254863A0 (en) Formulation and process for modulating wound healing
GB201417487D0 (en) Method for treating an animal substrate
IL251759B (en) Compositions and methods for treating insomnia
IL248555A0 (en) Methods for characterizing and treating acute myeloid leukemia
PL3386655T3 (pl) Sposób przetwarzania odpadów
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
ZA201807653B (en) New tetrahydropyrimidodiazepin and dihydropyridodiazepin compounds for treating pain and pain related conditions
DK3294769T3 (da) Behandling for multipelt myelom (mm)
SG11201607440YA (en) Composition and method for enhancing wound healing
FI20140361A7 (fi) Atomikerroskasvatus jossa ensimmäinen ja toinen lähdeainelaji ovat läsnä samanaikaisesti
EP3532063A4 (en) POLYTHERAPY FOR THE TREATMENT OF PULMONARY HYPERTENSION
SG10202010598SA (en) Detecting and treating growth hormone deficiency
FI20145633A7 (fi) Menetelmä biolietteen käsittelemiseksi
DK3743721T3 (da) Minaprin til anvendelse til reducering af tumorvækst
DK3305977T3 (da) Automatisk stoftilfører